Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

IO-108

Monoclonal antibody · Antagonist of LILRB2 · developed by Immune-Onc Therapeutics

Phase 1/2 Most advanced trial
1 Registered trials

What is IO-108?

IO-108 is a monoclonal antibody that binds to LILRB2, an inhibitory immune checkpoint receptor expressed on myeloid cells. By blocking LILRB2-mediated signaling, it relieves immunosuppression in the tumor microenvironment and enhances cytotoxic T-lymphocyte responses. It is being studied in advanced liver cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
LILRB2
Mechanism
Antagonist of LILRB2
Pathways
immune activation, cytotoxic T-lymphocyte response
Therapy area
Immunology, Oncology
Developer
Immune-Onc Therapeutics
In trials of
ADAG
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04524871 Phase 1/2 Advanced Liver Cancers Active not recruiting ADAG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Liver Cancers

Other drugs acting on LILRB2

CDX-585 Phase 1 CHS-1000 Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.